<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Patents Archives - X-Chem</title>
	<atom:link href="https://www.x-chemrx.com/portfolio_category/patents/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.x-chemrx.com/portfolio_category/patents/</link>
	<description>Take the Lead. Drive Discovery.</description>
	<lastBuildDate>Mon, 03 Nov 2025 19:07:52 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>
	<item>
		<title>Inhibitors of P97 Protein and Methods of Use</title>
		<link>https://www.x-chemrx.com/projects/inhibitors-of-p97-protein-and-methods-of-use/</link>
					<comments>https://www.x-chemrx.com/projects/inhibitors-of-p97-protein-and-methods-of-use/#respond</comments>
		
		<dc:creator><![CDATA[AdminGG]]></dc:creator>
		<pubDate>Wed, 19 Mar 2025 18:34:18 +0000</pubDate>
				<guid isPermaLink="false">https://ggdev9.com/?post_type=avada_portfolio&#038;p=3528</guid>

					<description><![CDATA[<p>Described herein are compounds and compositions useful for preventing and/or treating a disease or condition, e.g., a disease or condition associated with activity of p97 protein, e.g., cancer or a neurodegenerative disorder. In one aspect, the present disclosure provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the variables R1, R2,  [...]</p>
<p>The post <a href="https://www.x-chemrx.com/projects/inhibitors-of-p97-protein-and-methods-of-use/">Inhibitors of P97 Protein and Methods of Use</a> appeared first on <a href="https://www.x-chemrx.com">X-Chem</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap" style="max-width:1248px;margin-left: calc(-4% / 2 );margin-right: calc(-4% / 2 );"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_2_3 2_3 fusion-flex-column" style="--awb-bg-size:cover;--awb-width-large:66.666666666667%;--awb-spacing-right-large:2.88%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:2.88%;--awb-width-medium:66.666666666667%;--awb-order-medium:0;--awb-spacing-right-medium:2.88%;--awb-spacing-left-medium:2.88%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column"><div class="fusion-text fusion-text-1"><p>Described herein are compounds and compositions useful for preventing and/or treating a disease or condition, e.g., a disease or condition associated with activity of p97 protein, <em>e.g.</em>, cancer or a neurodegenerative disorder. In one aspect, the present disclosure provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the variables R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, m and n are as defined herein.</p>
</div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-1 fusion_builder_column_1_3 1_3 fusion-flex-column" style="--awb-bg-size:cover;--awb-width-large:33.333333333333%;--awb-spacing-right-large:5.76%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:5.76%;--awb-width-medium:33.333333333333%;--awb-order-medium:0;--awb-spacing-right-medium:5.76%;--awb-spacing-left-medium:5.76%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column"><div class="sm-text-align-left" style="text-align:center;"><a class="fusion-button button-flat fusion-button-default-size button-custom fusion-button-default button-1 fusion-button-span-yes fusion-has-button-gradient" style="--button_accent_color:var(--awb-color1);--button_accent_hover_color:var(--awb-color1);--button_border_hover_color:var(--awb-color1);--button_border_width-top:0;--button_border_width-right:0;--button_border_width-bottom:0;--button_border_width-left:0;--button-border-radius-top-left:0;--button-border-radius-top-right:0;--button-border-radius-bottom-right:0;--button-border-radius-bottom-left:0;--button_gradient_start:89%;--button_gradient_end:0%;--button_gradient_top_color:var(--awb-color5);--button_gradient_bottom_color:hsla(var(--awb-color5-h),var(--awb-color5-s),calc(var(--awb-color5-l) - 8%),var(--awb-color5-a));--button_gradient_top_color_hover:hsla(var(--awb-color5-h),var(--awb-color5-s),calc(var(--awb-color5-l) - 8%),var(--awb-color5-a));--button_gradient_bottom_color_hover:hsla(var(--awb-color5-h),var(--awb-color5-s),calc(var(--awb-color5-l) - 8%),var(--awb-color5-a));--button_font_size:18px;--button_padding-top:24px;--button_padding-right:48px;--button_padding-bottom:26px;--button_padding-left:48px;--button_margin-top:0px;--button_margin-right:0px;--button_margin-bottom:0px;--button_margin-left:0px;width:calc(100% - 0px - 0px);" target="_blank" rel="noopener noreferrer" data-hover="bg_slide_left" href="https://patentscope.wipo.int/search/en/WO2025014963"><span class="fusion-button-text awb-button__text awb-button__text--default">View Resource</span><i class="awb-factoryarrow-right awb-button__icon awb-button__icon--default button-icon-right" aria-hidden="true"></i></a></div></div></div></div></div>
<p>The post <a href="https://www.x-chemrx.com/projects/inhibitors-of-p97-protein-and-methods-of-use/">Inhibitors of P97 Protein and Methods of Use</a> appeared first on <a href="https://www.x-chemrx.com">X-Chem</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.x-chemrx.com/projects/inhibitors-of-p97-protein-and-methods-of-use/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Methods for identifying compounds binding to a target molecule using mirror-imaging of the target molecule</title>
		<link>https://www.x-chemrx.com/projects/methods-for-identifying-compounds-binding-to-a-target-molecule-using-mirror-imaging-of-the-target-molecule/</link>
					<comments>https://www.x-chemrx.com/projects/methods-for-identifying-compounds-binding-to-a-target-molecule-using-mirror-imaging-of-the-target-molecule/#respond</comments>
		
		<dc:creator><![CDATA[AdminGG]]></dc:creator>
		<pubDate>Fri, 07 Mar 2025 20:55:53 +0000</pubDate>
				<guid isPermaLink="false">https://ggdev9.com/?post_type=avada_portfolio&#038;p=3538</guid>

					<description><![CDATA[<p>The present disclosure provides methods of screening DNA-encoded chemical libraries utilizing mirror-images of target molecules. These methods allow highly efficient selection of compounds that bind to a target molecule, even when the target molecule can bind the DNA tag of the encoded compounds.  View Resource</p>
<p>The post <a href="https://www.x-chemrx.com/projects/methods-for-identifying-compounds-binding-to-a-target-molecule-using-mirror-imaging-of-the-target-molecule/">Methods for identifying compounds binding to a target molecule using mirror-imaging of the target molecule</a> appeared first on <a href="https://www.x-chemrx.com">X-Chem</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-2 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap" style="max-width:1248px;margin-left: calc(-4% / 2 );margin-right: calc(-4% / 2 );"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-2 fusion_builder_column_2_3 2_3 fusion-flex-column" style="--awb-bg-size:cover;--awb-width-large:66.666666666667%;--awb-spacing-right-large:2.88%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:2.88%;--awb-width-medium:66.666666666667%;--awb-order-medium:0;--awb-spacing-right-medium:2.88%;--awb-spacing-left-medium:2.88%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column"><div class="fusion-text fusion-text-2"><p>The present disclosure provides methods of screening DNA-encoded chemical libraries utilizing mirror-images of target molecules. These methods allow highly efficient selection of compounds that bind to a target molecule, even when the target molecule can bind the DNA tag of the encoded compounds.</p>
</div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-3 fusion_builder_column_1_3 1_3 fusion-flex-column" style="--awb-bg-size:cover;--awb-width-large:33.333333333333%;--awb-spacing-right-large:5.76%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:5.76%;--awb-width-medium:33.333333333333%;--awb-order-medium:0;--awb-spacing-right-medium:5.76%;--awb-spacing-left-medium:5.76%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column"><div ><a class="fusion-button button-flat fusion-button-default-size button-default fusion-button-default button-2 fusion-button-span-yes fusion-button-default-type" target="_blank" rel="noopener noreferrer" href="https://patents.google.com/patent/WO2025042899A2/en"><i class="fa-file-alt fas awb-button__icon awb-button__icon--default button-icon-left" aria-hidden="true"></i><span class="fusion-button-text awb-button__text awb-button__text--default">View Resource</span></a></div></div></div></div></div>
<p>The post <a href="https://www.x-chemrx.com/projects/methods-for-identifying-compounds-binding-to-a-target-molecule-using-mirror-imaging-of-the-target-molecule/">Methods for identifying compounds binding to a target molecule using mirror-imaging of the target molecule</a> appeared first on <a href="https://www.x-chemrx.com">X-Chem</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.x-chemrx.com/projects/methods-for-identifying-compounds-binding-to-a-target-molecule-using-mirror-imaging-of-the-target-molecule/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same</title>
		<link>https://www.x-chemrx.com/projects/crystalline-and-liquid-crystalline-25-hydroxy-cholest-5-en-3-sulfate-sodium-and-methods-for-preparing-same/</link>
					<comments>https://www.x-chemrx.com/projects/crystalline-and-liquid-crystalline-25-hydroxy-cholest-5-en-3-sulfate-sodium-and-methods-for-preparing-same/#respond</comments>
		
		<dc:creator><![CDATA[AdminGG]]></dc:creator>
		<pubDate>Thu, 01 Jul 2021 15:36:17 +0000</pubDate>
				<guid isPermaLink="false">https://ggdev9.com/?post_type=avada_portfolio&#038;p=3715</guid>

					<description><![CDATA[<p>Crystalline and liquid crystalline forms of 25HC3S sodium are described herein. The disclosure includes Forms I, II, III, V, IX, XI, and XIII of 25HC3S sodium and combinations thereof. Pharmaceutical formulations of said forms, or combinations thereof, and methods of treating or preventing disease such as hypercholesterolemia, hypertriglyceridemia, and conditions related to fat accumulation  [...]</p>
<p>The post <a href="https://www.x-chemrx.com/projects/crystalline-and-liquid-crystalline-25-hydroxy-cholest-5-en-3-sulfate-sodium-and-methods-for-preparing-same/">Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same</a> appeared first on <a href="https://www.x-chemrx.com">X-Chem</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-3 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap" style="max-width:1248px;margin-left: calc(-4% / 2 );margin-right: calc(-4% / 2 );"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-4 fusion_builder_column_2_3 2_3 fusion-flex-column" style="--awb-bg-size:cover;--awb-width-large:66.666666666667%;--awb-spacing-right-large:2.88%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:2.88%;--awb-width-medium:66.666666666667%;--awb-order-medium:0;--awb-spacing-right-medium:2.88%;--awb-spacing-left-medium:2.88%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column"><div class="fusion-text fusion-text-3"><p>Crystalline and liquid crystalline forms of 25HC3S sodium are described herein. The disclosure includes Forms I, II, III, V, IX, XI, and XIII of 25HC3S sodium and combinations thereof. Pharmaceutical formulations of said forms, or combinations thereof, and methods of treating or preventing disease such as hypercholesterolemia, hypertriglyceridemia, and conditions related to fat accumulation and inflammation (e.g., non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, and atherosclerosis) are further disclosed herein. Methods for preparing 25HC3S are also provided</p>
</div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-5 fusion_builder_column_1_3 1_3 fusion-flex-column" style="--awb-bg-size:cover;--awb-width-large:33.333333333333%;--awb-spacing-right-large:5.76%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:5.76%;--awb-width-medium:33.333333333333%;--awb-order-medium:0;--awb-spacing-right-medium:5.76%;--awb-spacing-left-medium:5.76%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column"><div ><a class="fusion-button button-flat fusion-button-default-size button-default fusion-button-default button-3 fusion-button-span-yes fusion-button-default-type" target="_blank" rel="noopener noreferrer" href="https://worldwide.espacenet.com/patent/search/family/076575692/publication/WO2021133976A1?q=WO2021133976A1"><i class="fa-file-alt fas awb-button__icon awb-button__icon--default button-icon-left" aria-hidden="true"></i><span class="fusion-button-text awb-button__text awb-button__text--default">Read Full Article</span></a></div><div class="fusion-text fusion-text-4" style="--awb-font-size:15px;--awb-margin-top:10px;">
</div></div></div></div></div>
<p>The post <a href="https://www.x-chemrx.com/projects/crystalline-and-liquid-crystalline-25-hydroxy-cholest-5-en-3-sulfate-sodium-and-methods-for-preparing-same/">Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same</a> appeared first on <a href="https://www.x-chemrx.com">X-Chem</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.x-chemrx.com/projects/crystalline-and-liquid-crystalline-25-hydroxy-cholest-5-en-3-sulfate-sodium-and-methods-for-preparing-same/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Collaborative Medicinal Development, LLC, USA .; Preparation of heteroaromatic and heterobicyclic aromatic derivatives for the treatment of ferroptosis-related disorders</title>
		<link>https://www.x-chemrx.com/projects/collaborative-medicinal-development-llc-usa-preparation-of-heteroaromatic-and-heterobicyclic-aromatic-derivatives-for-the-treatment-of-ferroptosis-related-disorders/</link>
					<comments>https://www.x-chemrx.com/projects/collaborative-medicinal-development-llc-usa-preparation-of-heteroaromatic-and-heterobicyclic-aromatic-derivatives-for-the-treatment-of-ferroptosis-related-disorders/#respond</comments>
		
		<dc:creator><![CDATA[AdminGG]]></dc:creator>
		<pubDate>Thu, 17 Sep 2020 16:15:58 +0000</pubDate>
				<guid isPermaLink="false">https://ggdev9.com/?post_type=avada_portfolio&#038;p=3744</guid>

					<description><![CDATA[<p>The present application discloses heteroaromatic and heterobicyclic aromatic derivative compounds and compositions, and methods for treating ferroptosis-related disorders and diseases in patients using the compounds and compositions as disclosed herein.  Read Full Article</p>
<p>The post <a href="https://www.x-chemrx.com/projects/collaborative-medicinal-development-llc-usa-preparation-of-heteroaromatic-and-heterobicyclic-aromatic-derivatives-for-the-treatment-of-ferroptosis-related-disorders/">Collaborative Medicinal Development, LLC, USA .; Preparation of heteroaromatic and heterobicyclic aromatic derivatives for the treatment of ferroptosis-related disorders</a> appeared first on <a href="https://www.x-chemrx.com">X-Chem</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-4 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap" style="max-width:1248px;margin-left: calc(-4% / 2 );margin-right: calc(-4% / 2 );"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-6 fusion_builder_column_2_3 2_3 fusion-flex-column" style="--awb-bg-size:cover;--awb-width-large:66.666666666667%;--awb-spacing-right-large:2.88%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:2.88%;--awb-width-medium:66.666666666667%;--awb-order-medium:0;--awb-spacing-right-medium:2.88%;--awb-spacing-left-medium:2.88%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column"><div class="fusion-text fusion-text-5"><p>The present application discloses heteroaromatic and heterobicyclic aromatic derivative compounds and compositions, and methods for treating ferroptosis-related disorders and diseases in patients using the compounds and compositions as disclosed herein.</p>
</div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-7 fusion_builder_column_1_3 1_3 fusion-flex-column" style="--awb-bg-size:cover;--awb-width-large:33.333333333333%;--awb-spacing-right-large:5.76%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:5.76%;--awb-width-medium:33.333333333333%;--awb-order-medium:0;--awb-spacing-right-medium:5.76%;--awb-spacing-left-medium:5.76%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column"><div ><a class="fusion-button button-flat fusion-button-default-size button-default fusion-button-default button-4 fusion-button-span-yes fusion-button-default-type" target="_blank" rel="noopener noreferrer" href="https://patents.google.com/patent/WO2020185738A1/en?oq=WO2020185738A1"><i class="fa-file-alt fas awb-button__icon awb-button__icon--default button-icon-left" aria-hidden="true"></i><span class="fusion-button-text awb-button__text awb-button__text--default">Read Full Article</span></a></div></div></div></div></div>
<p>The post <a href="https://www.x-chemrx.com/projects/collaborative-medicinal-development-llc-usa-preparation-of-heteroaromatic-and-heterobicyclic-aromatic-derivatives-for-the-treatment-of-ferroptosis-related-disorders/">Collaborative Medicinal Development, LLC, USA .; Preparation of heteroaromatic and heterobicyclic aromatic derivatives for the treatment of ferroptosis-related disorders</a> appeared first on <a href="https://www.x-chemrx.com">X-Chem</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.x-chemrx.com/projects/collaborative-medicinal-development-llc-usa-preparation-of-heteroaromatic-and-heterobicyclic-aromatic-derivatives-for-the-treatment-of-ferroptosis-related-disorders/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Mitokinin, Inc., USA .; Preparation of purinamines and pyrrolopyrimidinamines, compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease</title>
		<link>https://www.x-chemrx.com/projects/mitokinin-inc-usa-preparation-of-purinamines-and-pyrrolopyrimidinamines-compositions-and-methods-of-using-the-same-for-treatment-of-neurodegenerative-and-mitochondrial-disease/</link>
					<comments>https://www.x-chemrx.com/projects/mitokinin-inc-usa-preparation-of-purinamines-and-pyrrolopyrimidinamines-compositions-and-methods-of-using-the-same-for-treatment-of-neurodegenerative-and-mitochondrial-disease/#respond</comments>
		
		<dc:creator><![CDATA[AdminGG]]></dc:creator>
		<pubDate>Mon, 10 Aug 2020 16:16:34 +0000</pubDate>
				<guid isPermaLink="false">https://ggdev9.com/?post_type=avada_portfolio&#038;p=3746</guid>

					<description><![CDATA[<p>The present disclosure is directed to nitrogen-containing heteroaryl analogs, methods of making nitrogen-containing analogs, and methods of treating disorders associated with PINK1 kinase activity including, but not limited to, neurodegenerative diseases, mitochondrial diseases, fibrosis, and/or cardiomyopathy using these analogs. This abstract is intended as a scanning tool for purposes of searching in the particular  [...]</p>
<p>The post <a href="https://www.x-chemrx.com/projects/mitokinin-inc-usa-preparation-of-purinamines-and-pyrrolopyrimidinamines-compositions-and-methods-of-using-the-same-for-treatment-of-neurodegenerative-and-mitochondrial-disease/">Mitokinin, Inc., USA .; Preparation of purinamines and pyrrolopyrimidinamines, compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease</a> appeared first on <a href="https://www.x-chemrx.com">X-Chem</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-5 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap" style="max-width:1248px;margin-left: calc(-4% / 2 );margin-right: calc(-4% / 2 );"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-8 fusion_builder_column_2_3 2_3 fusion-flex-column" style="--awb-bg-size:cover;--awb-width-large:66.666666666667%;--awb-spacing-right-large:2.88%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:2.88%;--awb-width-medium:66.666666666667%;--awb-order-medium:0;--awb-spacing-right-medium:2.88%;--awb-spacing-left-medium:2.88%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column"><div class="fusion-text fusion-text-6"><p>The present disclosure is directed to nitrogen-containing heteroaryl analogs, methods of making nitrogen-containing analogs, and methods of treating disorders associated with PINK1 kinase activity including, but not limited to, neurodegenerative diseases, mitochondrial diseases, fibrosis, and/or cardiomyopathy using these analogs. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.</p>
</div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-9 fusion_builder_column_1_3 1_3 fusion-flex-column" style="--awb-bg-size:cover;--awb-width-large:33.333333333333%;--awb-spacing-right-large:5.76%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:5.76%;--awb-width-medium:33.333333333333%;--awb-order-medium:0;--awb-spacing-right-medium:5.76%;--awb-spacing-left-medium:5.76%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column"><div ><a class="fusion-button button-flat fusion-button-default-size button-default fusion-button-default button-5 fusion-button-span-yes fusion-button-default-type" target="_blank" rel="noopener noreferrer" href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020206363"><i class="fa-file-alt fas awb-button__icon awb-button__icon--default button-icon-left" aria-hidden="true"></i><span class="fusion-button-text awb-button__text awb-button__text--default">Read Full Article</span></a></div></div></div></div></div>
<p>The post <a href="https://www.x-chemrx.com/projects/mitokinin-inc-usa-preparation-of-purinamines-and-pyrrolopyrimidinamines-compositions-and-methods-of-using-the-same-for-treatment-of-neurodegenerative-and-mitochondrial-disease/">Mitokinin, Inc., USA .; Preparation of purinamines and pyrrolopyrimidinamines, compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease</a> appeared first on <a href="https://www.x-chemrx.com">X-Chem</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.x-chemrx.com/projects/mitokinin-inc-usa-preparation-of-purinamines-and-pyrrolopyrimidinamines-compositions-and-methods-of-using-the-same-for-treatment-of-neurodegenerative-and-mitochondrial-disease/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Fulcrum Therapeutics, Inc., USA .; Macrocyclic azolopyridine derivatives as EED and PRC2 modulators and their preparation</title>
		<link>https://www.x-chemrx.com/projects/fulcrum-therapeutics-inc-usa-macrocyclic-azolopyridine-derivatives-as-eed-and-prc2-modulators-and-their-preparation/</link>
					<comments>https://www.x-chemrx.com/projects/fulcrum-therapeutics-inc-usa-macrocyclic-azolopyridine-derivatives-as-eed-and-prc2-modulators-and-their-preparation/#respond</comments>
		
		<dc:creator><![CDATA[AdminGG]]></dc:creator>
		<pubDate>Fri, 13 Mar 2020 16:18:17 +0000</pubDate>
				<guid isPermaLink="false">https://ggdev9.com/?post_type=avada_portfolio&#038;p=3752</guid>

					<description><![CDATA[<p>The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula (I), or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X1,  [...]</p>
<p>The post <a href="https://www.x-chemrx.com/projects/fulcrum-therapeutics-inc-usa-macrocyclic-azolopyridine-derivatives-as-eed-and-prc2-modulators-and-their-preparation/">Fulcrum Therapeutics, Inc., USA .; Macrocyclic azolopyridine derivatives as EED and PRC2 modulators and their preparation</a> appeared first on <a href="https://www.x-chemrx.com">X-Chem</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-6 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap" style="max-width:1248px;margin-left: calc(-4% / 2 );margin-right: calc(-4% / 2 );"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-10 fusion_builder_column_2_3 2_3 fusion-flex-column" style="--awb-bg-size:cover;--awb-width-large:66.666666666667%;--awb-spacing-right-large:2.88%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:2.88%;--awb-width-medium:66.666666666667%;--awb-order-medium:0;--awb-spacing-right-medium:2.88%;--awb-spacing-left-medium:2.88%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column"><div class="fusion-text fusion-text-7"><p>The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula (I), or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, A<sub>1</sub>, A<sub>2</sub>, Y, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, and R<sub>4</sub> are as described herein.</p>
</div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-11 fusion_builder_column_1_3 1_3 fusion-flex-column" style="--awb-bg-size:cover;--awb-width-large:33.333333333333%;--awb-spacing-right-large:5.76%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:5.76%;--awb-width-medium:33.333333333333%;--awb-order-medium:0;--awb-spacing-right-medium:5.76%;--awb-spacing-left-medium:5.76%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column"><div ><a class="fusion-button button-flat fusion-button-default-size button-default fusion-button-default button-6 fusion-button-span-yes fusion-button-default-type" target="_blank" rel="noopener noreferrer" href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020190754"><i class="fa-file-alt fas awb-button__icon awb-button__icon--default button-icon-left" aria-hidden="true"></i><span class="fusion-button-text awb-button__text awb-button__text--default">Read Full Article</span></a></div></div></div></div></div>
<p>The post <a href="https://www.x-chemrx.com/projects/fulcrum-therapeutics-inc-usa-macrocyclic-azolopyridine-derivatives-as-eed-and-prc2-modulators-and-their-preparation/">Fulcrum Therapeutics, Inc., USA .; Macrocyclic azolopyridine derivatives as EED and PRC2 modulators and their preparation</a> appeared first on <a href="https://www.x-chemrx.com">X-Chem</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.x-chemrx.com/projects/fulcrum-therapeutics-inc-usa-macrocyclic-azolopyridine-derivatives-as-eed-and-prc2-modulators-and-their-preparation/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Achaogen, Inc., USA .; Modular synthesis of aminoglycosides as antibacterial agents</title>
		<link>https://www.x-chemrx.com/projects/achaogen-inc-usa-modular-synthesis-of-aminoglycosides-as-antibacterial-agents/</link>
					<comments>https://www.x-chemrx.com/projects/achaogen-inc-usa-modular-synthesis-of-aminoglycosides-as-antibacterial-agents/#respond</comments>
		
		<dc:creator><![CDATA[AdminGG]]></dc:creator>
		<pubDate>Thu, 10 Oct 2019 16:18:48 +0000</pubDate>
				<guid isPermaLink="false">https://ggdev9.com/?post_type=avada_portfolio&#038;p=3754</guid>

					<description><![CDATA[<p>The present disclosure relates to novel methods for preparing antibacterial aminoglycoside compounds and the compounds used in such preparations.  Read Full Article</p>
<p>The post <a href="https://www.x-chemrx.com/projects/achaogen-inc-usa-modular-synthesis-of-aminoglycosides-as-antibacterial-agents/">Achaogen, Inc., USA .; Modular synthesis of aminoglycosides as antibacterial agents</a> appeared first on <a href="https://www.x-chemrx.com">X-Chem</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-7 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap" style="max-width:1248px;margin-left: calc(-4% / 2 );margin-right: calc(-4% / 2 );"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-12 fusion_builder_column_2_3 2_3 fusion-flex-column" style="--awb-bg-size:cover;--awb-width-large:66.666666666667%;--awb-spacing-right-large:2.88%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:2.88%;--awb-width-medium:66.666666666667%;--awb-order-medium:0;--awb-spacing-right-medium:2.88%;--awb-spacing-left-medium:2.88%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column"><div class="fusion-text fusion-text-8"><p>The present disclosure relates to novel methods for preparing antibacterial aminoglycoside compounds and the compounds used in such preparations.</p>
</div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-13 fusion_builder_column_1_3 1_3 fusion-flex-column" style="--awb-bg-size:cover;--awb-width-large:33.333333333333%;--awb-spacing-right-large:5.76%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:5.76%;--awb-width-medium:33.333333333333%;--awb-order-medium:0;--awb-spacing-right-medium:5.76%;--awb-spacing-left-medium:5.76%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column"><div ><a class="fusion-button button-flat fusion-button-default-size button-default fusion-button-default button-7 fusion-button-span-yes fusion-button-default-type" target="_blank" rel="noopener noreferrer" href="https://patents.google.com/patent/WO2019194858A1/en"><i class="fa-file-alt fas awb-button__icon awb-button__icon--default button-icon-left" aria-hidden="true"></i><span class="fusion-button-text awb-button__text awb-button__text--default">Read Full Article</span></a></div></div></div></div></div>
<p>The post <a href="https://www.x-chemrx.com/projects/achaogen-inc-usa-modular-synthesis-of-aminoglycosides-as-antibacterial-agents/">Achaogen, Inc., USA .; Modular synthesis of aminoglycosides as antibacterial agents</a> appeared first on <a href="https://www.x-chemrx.com">X-Chem</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.x-chemrx.com/projects/achaogen-inc-usa-modular-synthesis-of-aminoglycosides-as-antibacterial-agents/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Medimmune Limited, UK .; Cyclohexenone derivatives as small molecule modulators of the BTB domain of KEAP1 and their preparation, pharmaceutical compositions and use in the treatment of diseases</title>
		<link>https://www.x-chemrx.com/projects/medimmune-limited-uk-cyclohexenone-derivatives-as-small-molecule-modulators-of-the-btb-domain-of-keap1-and-their-preparation-pharmaceutical-compositions-and-use-in-the-treatment-of-diseases/</link>
					<comments>https://www.x-chemrx.com/projects/medimmune-limited-uk-cyclohexenone-derivatives-as-small-molecule-modulators-of-the-btb-domain-of-keap1-and-their-preparation-pharmaceutical-compositions-and-use-in-the-treatment-of-diseases/#respond</comments>
		
		<dc:creator><![CDATA[AdminGG]]></dc:creator>
		<pubDate>Thu, 27 Jun 2019 16:20:01 +0000</pubDate>
				<guid isPermaLink="false">https://ggdev9.com/?post_type=avada_portfolio&#038;p=3756</guid>

					<description><![CDATA[<p>The present application relates to compounds of formula (I’) or formula (I), such as formula (Ia), and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing neurodegenerative disorders, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington disease (HD) and other CAG-triplet repeat (or polyglutamine) diseases, amyotrophic lateral sclerosis (ALS;  [...]</p>
<p>The post <a href="https://www.x-chemrx.com/projects/medimmune-limited-uk-cyclohexenone-derivatives-as-small-molecule-modulators-of-the-btb-domain-of-keap1-and-their-preparation-pharmaceutical-compositions-and-use-in-the-treatment-of-diseases/">Medimmune Limited, UK .; Cyclohexenone derivatives as small molecule modulators of the BTB domain of KEAP1 and their preparation, pharmaceutical compositions and use in the treatment of diseases</a> appeared first on <a href="https://www.x-chemrx.com">X-Chem</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-8 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap" style="max-width:1248px;margin-left: calc(-4% / 2 );margin-right: calc(-4% / 2 );"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-14 fusion_builder_column_2_3 2_3 fusion-flex-column" style="--awb-bg-size:cover;--awb-width-large:66.666666666667%;--awb-spacing-right-large:2.88%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:2.88%;--awb-width-medium:66.666666666667%;--awb-order-medium:0;--awb-spacing-right-medium:2.88%;--awb-spacing-left-medium:2.88%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column"><div class="fusion-text fusion-text-9"><p>The present application relates to compounds of formula (I’) or formula (I), such as formula (Ia), and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing neurodegenerative disorders, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington disease (HD) and other CAG-triplet repeat (or polyglutamine) diseases, amyotrophic lateral sclerosis (ALS; Lou Gehrig’s disease), diffuse Lewy body disease, chorea-acanthocytosis, primary lateral sclerosis, multiple sclerosis (MS), frontotemporal dementia, Friedreich’s ataxia, acute head injury, and epilepsy (repression of microglia activation).</p>
</div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-15 fusion_builder_column_1_3 1_3 fusion-flex-column" style="--awb-bg-size:cover;--awb-width-large:33.333333333333%;--awb-spacing-right-large:5.76%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:5.76%;--awb-width-medium:33.333333333333%;--awb-order-medium:0;--awb-spacing-right-medium:5.76%;--awb-spacing-left-medium:5.76%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column"><div ><a class="fusion-button button-flat fusion-button-default-size button-default fusion-button-default button-8 fusion-button-span-yes fusion-button-default-type" target="_blank" rel="noopener noreferrer" href="https://patents.google.com/patent/WO2019122265A1/en"><i class="fa-file-alt fas awb-button__icon awb-button__icon--default button-icon-left" aria-hidden="true"></i><span class="fusion-button-text awb-button__text awb-button__text--default">Read Full Article</span></a></div></div></div></div></div>
<p>The post <a href="https://www.x-chemrx.com/projects/medimmune-limited-uk-cyclohexenone-derivatives-as-small-molecule-modulators-of-the-btb-domain-of-keap1-and-their-preparation-pharmaceutical-compositions-and-use-in-the-treatment-of-diseases/">Medimmune Limited, UK .; Cyclohexenone derivatives as small molecule modulators of the BTB domain of KEAP1 and their preparation, pharmaceutical compositions and use in the treatment of diseases</a> appeared first on <a href="https://www.x-chemrx.com">X-Chem</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.x-chemrx.com/projects/medimmune-limited-uk-cyclohexenone-derivatives-as-small-molecule-modulators-of-the-btb-domain-of-keap1-and-their-preparation-pharmaceutical-compositions-and-use-in-the-treatment-of-diseases/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Geneyus LLC, USA .; Preparation of substituted quinolines as Rac inhibitors useful for treating cancer</title>
		<link>https://www.x-chemrx.com/projects/geneyus-llc-usa-preparation-of-substituted-quinolines-as-rac-inhibitors-useful-for-treating-cancer/</link>
					<comments>https://www.x-chemrx.com/projects/geneyus-llc-usa-preparation-of-substituted-quinolines-as-rac-inhibitors-useful-for-treating-cancer/#respond</comments>
		
		<dc:creator><![CDATA[AdminGG]]></dc:creator>
		<pubDate>Thu, 07 Mar 2019 17:22:07 +0000</pubDate>
				<guid isPermaLink="false">https://ggdev9.com/?post_type=avada_portfolio&#038;p=3760</guid>

					<description><![CDATA[<p>The present invention relates to compounds that act as pan-Rac inhibitors, compositions including the compounds, and methods of using the compounds. In particular, the compounds are useful for treating certain cancers such as breast cancer.  Read Full Article</p>
<p>The post <a href="https://www.x-chemrx.com/projects/geneyus-llc-usa-preparation-of-substituted-quinolines-as-rac-inhibitors-useful-for-treating-cancer/">Geneyus LLC, USA .; Preparation of substituted quinolines as Rac inhibitors useful for treating cancer</a> appeared first on <a href="https://www.x-chemrx.com">X-Chem</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-9 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap" style="max-width:1248px;margin-left: calc(-4% / 2 );margin-right: calc(-4% / 2 );"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-16 fusion_builder_column_2_3 2_3 fusion-flex-column" style="--awb-bg-size:cover;--awb-width-large:66.666666666667%;--awb-spacing-right-large:2.88%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:2.88%;--awb-width-medium:66.666666666667%;--awb-order-medium:0;--awb-spacing-right-medium:2.88%;--awb-spacing-left-medium:2.88%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column"><div class="fusion-text fusion-text-10"><p>The present invention relates to compounds that act as pan-Rac inhibitors, compositions including the compounds, and methods of using the compounds. In particular, the compounds are useful for treating certain cancers such as breast cancer.</p>
</div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-17 fusion_builder_column_1_3 1_3 fusion-flex-column" style="--awb-bg-size:cover;--awb-width-large:33.333333333333%;--awb-spacing-right-large:5.76%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:5.76%;--awb-width-medium:33.333333333333%;--awb-order-medium:0;--awb-spacing-right-medium:5.76%;--awb-spacing-left-medium:5.76%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column"><div ><a class="fusion-button button-flat fusion-button-default-size button-default fusion-button-default button-9 fusion-button-span-yes fusion-button-default-type" target="_blank" rel="noopener noreferrer" href="https://patents.google.com/patent/WO2019023315A2/en"><i class="fa-file-alt fas awb-button__icon awb-button__icon--default button-icon-left" aria-hidden="true"></i><span class="fusion-button-text awb-button__text awb-button__text--default">Read Full Article</span></a></div></div></div></div></div>
<p>The post <a href="https://www.x-chemrx.com/projects/geneyus-llc-usa-preparation-of-substituted-quinolines-as-rac-inhibitors-useful-for-treating-cancer/">Geneyus LLC, USA .; Preparation of substituted quinolines as Rac inhibitors useful for treating cancer</a> appeared first on <a href="https://www.x-chemrx.com">X-Chem</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.x-chemrx.com/projects/geneyus-llc-usa-preparation-of-substituted-quinolines-as-rac-inhibitors-useful-for-treating-cancer/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>AstraZeneca AB, Swed. .; Preparation of substituted imidazole and triazole compounds as inhibitors of protease-activated receptor-2</title>
		<link>https://www.x-chemrx.com/projects/astrazeneca-ab-swed-preparation-of-substituted-imidazole-and-triazole-compounds-as-inhibitors-of-protease-activated-receptor-2/</link>
					<comments>https://www.x-chemrx.com/projects/astrazeneca-ab-swed-preparation-of-substituted-imidazole-and-triazole-compounds-as-inhibitors-of-protease-activated-receptor-2/#respond</comments>
		
		<dc:creator><![CDATA[AdminGG]]></dc:creator>
		<pubDate>Sat, 11 Nov 2017 17:23:55 +0000</pubDate>
				<guid isPermaLink="false">https://ggdev9.com/?post_type=avada_portfolio&#038;p=3766</guid>

					<description><![CDATA[<p>The present application relates to certain substituted imidazole and triazole compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating pain, musculoskeletal inflammation, neuroinflammatory disorders, airway inflammation, itch, dermatitis, colitis and related conditions. The compounds are of Formula (I) where X is N or CH, Z and Y are N  [...]</p>
<p>The post <a href="https://www.x-chemrx.com/projects/astrazeneca-ab-swed-preparation-of-substituted-imidazole-and-triazole-compounds-as-inhibitors-of-protease-activated-receptor-2/">AstraZeneca AB, Swed. .; Preparation of substituted imidazole and triazole compounds as inhibitors of protease-activated receptor-2</a> appeared first on <a href="https://www.x-chemrx.com">X-Chem</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="fusion-fullwidth fullwidth-box fusion-builder-row-10 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling" style="--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;" ><div class="fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap" style="max-width:1248px;margin-left: calc(-4% / 2 );margin-right: calc(-4% / 2 );"><div class="fusion-layout-column fusion_builder_column fusion-builder-column-18 fusion_builder_column_2_3 2_3 fusion-flex-column" style="--awb-bg-size:cover;--awb-width-large:66.666666666667%;--awb-spacing-right-large:2.88%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:2.88%;--awb-width-medium:66.666666666667%;--awb-order-medium:0;--awb-spacing-right-medium:2.88%;--awb-spacing-left-medium:2.88%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column"><div class="fusion-text fusion-text-11"><p>The present application relates to certain substituted imidazole and triazole compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating pain, musculoskeletal inflammation, neuroinflammatory disorders, airway inflammation, itch, dermatitis, colitis and related conditions. The compounds are of Formula (I) where X is N or CH, Z and Y are N or C (but both not N) and R<sup>1</sup>-R<sup>3</sup> are as defined herein.</p>
</div></div></div><div class="fusion-layout-column fusion_builder_column fusion-builder-column-19 fusion_builder_column_1_3 1_3 fusion-flex-column" style="--awb-bg-size:cover;--awb-width-large:33.333333333333%;--awb-spacing-right-large:5.76%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:5.76%;--awb-width-medium:33.333333333333%;--awb-order-medium:0;--awb-spacing-right-medium:5.76%;--awb-spacing-left-medium:5.76%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;"><div class="fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column"><div ><a class="fusion-button button-flat fusion-button-default-size button-default fusion-button-default button-10 fusion-button-span-yes fusion-button-default-type" target="_blank" rel="noopener noreferrer" href="https://patents.google.com/patent/WO2017194716A1/en"><i class="fa-file-alt fas awb-button__icon awb-button__icon--default button-icon-left" aria-hidden="true"></i><span class="fusion-button-text awb-button__text awb-button__text--default">Read Full Article</span></a></div></div></div></div></div>
<p>The post <a href="https://www.x-chemrx.com/projects/astrazeneca-ab-swed-preparation-of-substituted-imidazole-and-triazole-compounds-as-inhibitors-of-protease-activated-receptor-2/">AstraZeneca AB, Swed. .; Preparation of substituted imidazole and triazole compounds as inhibitors of protease-activated receptor-2</a> appeared first on <a href="https://www.x-chemrx.com">X-Chem</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.x-chemrx.com/projects/astrazeneca-ab-swed-preparation-of-substituted-imidazole-and-triazole-compounds-as-inhibitors-of-protease-activated-receptor-2/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
	</channel>
</rss>
